Das Klinikum

Herr Tamam Bakchoul

Herr Tamam Bakchoul

Ärztlicher Direktor

Kontakt

Telefonnummer: Sekretariat: 07071 29-81602

Faxnummer: 07071 29-5240

E-Mail-Adresse: zkt.sekretariat@med.uni-tuebingen.de

Klinik / Institut / Zentrum

  • Facharzt für Hämostaseologie
  • Facharzt für Transfusionmedizin
  • Forschungsschwerpunkte:
    - Thromboinflammation - crossover of clinical perspective and underlying
    pathophysiology
    - Thrombopoiesis modulation
    - Immune-mediated thrombosis and thrombocytopenia
    - Diagnosis and treatment of bleeding disorders
    - Novel approaches to platelet transfusion
  • seit 2020Ärztlicher Direktor Institut für Klinische und Experimentelle Transfusionsmedizin (IKET)
  • seit 2017Professur für Transfusionsmedizin an der Eberhard Karl Universität Tübingen
  • seit 2016Ärztlicher Direktor Zentrum für Klinische Transfusionsmedizin Tübingen
  • 2013-2016Oberarzt am Institut für Immunologie und Transfusionsmedizin Greifswald
  • 2012-2016Juniorprofessur für Klinische Immunhämotologie und Hämostaseologie an der Universität Greiswald
  • 2015Habilitations im Fach Transfusionsmedizin an der Universitätsmedizin Greifswald
  • 2015Zusatz-Weiterbildung Hämostaseologie
  • 2012-2016Leiter des HLA und Thrombozytenlabors im Institut für Immunologie und Transfusionsmedizin am Universitätsklinikum Gießen
  • 2011Facharzt für Transfusionsmedizin
  • Alexander-Schmidt-Preis 2023
  • Günther Landbeck Excellence Award
  • Young Investigator Award for Bleeding Disorders of GTH
  • Young Investigator Award of ISTH
  • Best Abstract Award 55. DGTI
  • Fritz-Schiff-Preis der Deutschen Gesellschaft für Transfusionsmedizin und Immunhämatologie (DGTI) für Nachwuchswissenschaftler
  • Schwerpunkt Thromboinflammation - crossover of clinical perspective and underlying pathophysiology
  • Platelet phosphatidylserine is the critical mediator of thrombosis in heparin-induced thrombocytopenia. Haematologica 2023; https://pubmed.ncbi.nlm.nih.gov/37102605/
  • No Correlation between Anti-PF4 and Anti-SARS-CoV-2 Antibodies after ChAdOx1 nCoV-19 Vaccination. N Engl J Med. 2021; https://pubmed.ncbi.nlm.nih.gov/34432977/
  • The use of IV immunoglobulin in the treatment of vaccine-induced immune thrombotic thrombocytopenia. Blood 2021; https://pubmed.ncbi.nlm.nih.gov/34166507/
  • Schwerpunkt Thrombopiesis modulation:
  • Autoantibody-mediated desialylation impairs human thrombopoiesis and platelet lifespan. Haematologica 2021; https://pubmed.ncbi.nlm.nih.gov/31857361/
  • Pathophysiology of Autoimmune Thrombocytopenia: Current Insight with a Focus on Thrombopoiesis. Hamostaseologie 2019; https://pubmed.ncbi.nlm.nih.gov/30802916/
  • Blood donor-derived buffy coat to produce platelets in vitro. Vox Sang 2020; https://pubmed.ncbi.nlm.nih.gov/31709567/
  • Schwerpunkt Immune-mediated thrombosis and thrombocytopenia:
  • Heparin-activated procoagulant platelet assay: a flow cytometry-based functional test for heparin-induced thrombocytopenia. J Thromb Haemost. 2024; https://pubmed.ncbi.nlm.nih.gov/37838242/
  • Diagnostic value of antibody-induced procoagulant platelets in heparin-induced thrombocytopenia: communication from the ISTH SSC Subcommittee on Platelet Immunology. J Thromb Haemost. 2024; https://pubmed.ncbi.nlm.nih.gov/38065529/
  • Cerebral venous sinus thrombosis and thrombocytopenia due to heparin-independent anti-PF4 antibodies after adenovirus infection. Haematologica 2023; https://pubmed.ncbi.nlm.nih.gov/37881869/
  • The interaction between anti-PF4 antibodies and anticoagulants in vaccine-induced thrombotic thrombocytopenia. Blood 2022; https://pubmed.ncbi.nlm.nih.gov/35679071/
  • Upregulation of cAMP prevents antibody-mediated thrombus formation in COVID-19. 2021. Blood Advances 2022; https://pubmed.ncbi.nlm.nih.gov/34753174/
  • Antibody-induced procoagulant platelets in severe COVID-19 infection. Blood 2021; https://pubmed.ncbi.nlm.nih.gov/33512415/
  • Antibody-mediated procoagulant platelets in SARS-CoV-2-vaccination associated immune thrombotic thrombocytopenia. Haematologica 2021; https://pubmed.ncbi.nlm.nih.gov/34011137/
  • Assessment of human platelet survival in the NOD/SCID mouse model: technical considerations. Transfusion 2016; https://pubmed.ncbi.nlm.nih.gov/27086568/
  • Schwerpunkt Diagnosis and treatment of bleeding disorders:
  • Platelet-neutrophil interaction in COVID-19 and vaccine-induced thrombotic thrombocytopenia. Front Immunol. 2023; https://pubmed.ncbi.nlm.nih.gov/37275917/
  • Diagnosis of Platelet Function Disorders: A Challenge for Laboratories. Hamostaseologie 2022; https://pubmed.ncbi.nlm.nih.gov/35196730/
  • Standardization of Light Transmission Aggregometry for Diagnosis of Platelet Disorders: An Inter-Laboratory External Quality Assessment. Thromb Haemost. 2019; https://pubmed.ncbi.nlm.nih.gov/31154663/
  • Recessive grey platelet-like syndrome with unaffected erythropoiesis in the absence of the splice isoform GFI1B-p37. Haematologica 2017; https://pubmed.ncbi.nlm.nih.gov/28550182/
  • Schwerpunkt Novel approaches to platelet transfuion:
  • Inhibition of GPIb-α-mediated apoptosis signaling enables cold storage of platelets. Haematologica 2023; https://pubmed.ncbi.nlm.nih.gov/37345472/
  • Cold storage of platelets in additive solution: the impact of residual plasma in apheresis platelet concentrates. Haematologica 2019; https://pubmed.ncbi.nlm.nih.gov/30115655/
  • Publikationen
  • Pflichtveranstaltung Humanmedizin "Transfusionsmedizin"
  • Wahlfachpflichtfach "Transfusionsmedizin und Hämostaseologie"
  • GTH, Vorstand
  • DGTI (Vorstand)
  • SSC Co-Chair
  • ASH Member
  • ISBT Member
  • DFG Fachkollegium
  • Weiterbildungsbefugter für Transfusionsmedizin und Haemostaseologie